552331-30-3

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
5-bromo-1,3-dimethyl-1H-indazole is used as a chemical intermediate for the synthesis of novel pharmaceutical compounds. Its unique structure and potential biological activities make it a promising candidate for the development of new drugs with various therapeutic applications.
Used in Antimicrobial Applications:
5-bromo-1,3-dimethyl-1H-indazole is used as an antimicrobial agent for its potential to inhibit the growth of bacteria and other microorganisms. Its ability to target specific cellular processes in microbes makes it a valuable tool in the fight against antibiotic-resistant infections.
Used in Antifungal Applications:
5-bromo-1,3-dimethyl-1H-indazole is used as an antifungal agent, particularly against various fungal species that cause infections in humans and other organisms. Its antifungal properties can be harnessed to develop new treatments for fungal infections and to improve existing antifungal therapies.
Used in Antiviral Applications:
5-bromo-1,3-dimethyl-1H-indazole is used as an antiviral agent, showing potential to inhibit the replication and spread of viruses. Its antiviral properties can be explored for the development of new antiviral drugs, especially in the context of emerging viral diseases and drug-resistant strains.
Used in Cancer Treatment Research:
5-bromo-1,3-dimethyl-1H-indazole is used as a potential anticancer agent in cancer treatment research. Its ability to target specific cellular pathways and processes involved in cancer cell growth and proliferation makes it a promising candidate for the development of new cancer therapies.
Used in Organic Synthesis:
5-bromo-1,3-dimethyl-1H-indazole is used as a building block in organic synthesis, particularly in the development of novel pharmaceutical compounds. Its unique structure and reactivity make it a valuable component in the synthesis of complex organic molecules with potential applications in medicine and other fields.

Upstream product

• 552331-16-5 5-bromo-3-methyl-1H-indazole 
• 74-88-4 methyl iodide 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 
• 60-34-4 methylhydrazine 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 552331-15-4 1-(5-bromo-2-fluorophenyl)ethan-1-ol 

Downstream Products

• 1095535-45-7 (1R,2R)-N-(1-cyanocyclopropyl)-2-{[(R)-4-(1,3-dimethyl-1H-indazol-5-yl)-2-methylpiperazin-1-yl]carbonyl}cyclohexanecarboxamide 
• 1220696-53-6 1,3-dimethyl-5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-1H-indazole 

Relevant academic research and scientific papers

HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY

A compound of formula (I) useful in the treatment of a Pneumoviridae viral infection.

HETEROAROMATIC COMPOUNDS USEFUL IN THERAPY

A compound of formula (I) or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection or a disease linked to impaired or abnormal autophagy.

CONDENSED PYRIMIDINE OR PYRIDAZINE DERIVATIVES AS ANTIVIRAL AGENTS

A compound of formula (I) or a pharmaceutically acceptable salt thereof. The compound is a prodrug of a PI4KIIIβinhibitor and as such is useful as an antiviral agent. A pharmaceutical composition comprising the compound.

2,6-DIMETHYL-N-((PYRIDIN-4-YL)METHYL)IMIDAZO[1,2-B]PYRIDAZIN-8-AMINE AND 2,5-DIMETHYL-N-[(PYRIDIN-4-YL)METHYL]PYRAZOLO[1,5-A]PYRIMIDIN-7-AMINE DERIVATIVES FOR TREATING VIRAL INFECTIONS

The compound is useful in therapy, in particular as an antiviral agent, e.g. in the treatment of an RNA viral infection. A pharmaceutical composition comprising the compound.

THIADIAZINE DERIVATIVES

The invention relates to thiadiazine derivatives, or pharmaceutically acceptable salts, biologically active metabolites, pro-drugs, racemates, enantiomers, diastereomers, solvates and hydrates thereof, as well as to pharmaceutical compositions containing

FUSED PYRAZOLE DERIVATIVES AS KINASE INHIBITORS

A series of substituted pyrazolo[1,5-a]pyrimidine and pyrazolo[1,5-a][1,3,5]- triazine derivatives of formula (I), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase ΙΙΙβ (ΡI4ΚΙΙΙβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

Amine-free melanin-concentrating hormone receptor 1 antagonists: Novel non-basic 1-(2H-indazole-5-yl)pyridin-2(1H)-one derivatives and mitigation of mutagenicity in Ames test

To develop non-basic melanin-concentrating hormone receptor 1 (MCHR1) antagonists with a high probability of target selectivity and therapeutic window, we explored neutral bicyclic motifs that could replace the previously reported imidazo[1,2-a]pyridine or 1H-benzimidazole motif. The results indicated that the binding affinity of a chemically neutral 2H-indazole derivative 8a with MCHR1 (hMCHR1: IC50 = 35 nM) was comparable to that of the imidazopyridine and benzimidazole derivatives (1 and 2, respectively) reported so far. However, 8a was positive in the Ames test using TA1537 in S9- condition. Based on a putative intercalation of 8a with DNA, we introduced a sterically-hindering cyclopropyl group on the indazole ring to decrease planarity, which led to the discovery of 1-(2-cyclopropyl-3-methyl-2H-indazol-5-yl)-4-{[5-(trifluoromethyl)thiophen-3-yl]methoxy}pyridin-2(1H)-one 8l without mutagenicity in TA1537. Compound 8l exerted significant antiobesity effects in diet-induced obese F344 rats and exhibited promising safety profile.

GLUCOSYLCERAMIDE SYNTHASE INHIBITORS FOR THE TREATMENT OF DISEASES

Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).

Selective methylation of NH-containing heterocycles and sulfonamides using n, N -dimethylformamide dimethylacetal based on calculated pKa Measurements

The use of N,N-dimethylformamide dimethylacetal (DMF-DMA) as a suitable methylating agent for the methylation of NH-containing groups and heterocycles has been investigated. Use of ReactArray and calculated pKa measurements have allowed additional helpful information to be collated to determine optimum reaction conditions for a variety of substrates.

Synthesis and SAR of indazole-pyridine based protein kinase B/Akt inhibitors

A series of heteroaryl-pyridine containing inhibitors of Akt are reported. The synthesis and structure-activity relationships are discussed, leading to the discovery of a indazole-pyridine analogue (Ki = 0.16 nM). These compounds bind in the ATP binding site, are potent, ATP competitive, and reversible inhibitors of Akt activity. No selectivity amongst the Akt isoforms is observed for this analogue, but there is good selectivity against an panel of other kinases. It is least selective for other members of the AGC family of kinases but is nonetheless 40-fold selective for Akt over PKA. The compound shows cellular activity and significantly slows tumor growth in vivo.